Hannah Gwin, MD
Internal Medicine · Gulfport, MSNPI 1740711316
Payments from drug & device makers
Across 275 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$746
- Amgen$600
- AstraZeneca$574
- GSK$532
- Sumitomo Pharma America, Inc.$355
- Bayer$351
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,743100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 49 | $746 |
| Amgen | 23 | $600 |
| AstraZeneca | 29 | $574 |
| GSK | 47 | $532 |
| Sumitomo Pharma America, Inc. | 21 | $355 |
| Bayer | 19 | $351 |
| Pfizer | 15 | $262 |
| Novo Nordisk | 14 | $247 |
| Boehringer Ingelheim | 9 | $149 |
| Vanda Pharmaceuticals Inc. | 4 | $108 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $101 |
| Astellas Pharma US Inc | 4 | $84 |
| Exact Sciences | 4 | $77 |
| Averitas Pharma Inc. | 3 | $65 |
| Esperion Therapeutics, Inc. | 4 | $62 |
| Corcept Therapeutics | 3 | $60 |
| AbbVie | 4 | $58 |
| Kowa Pharmaceuticals America, Inc. | 3 | $41 |
| Abbott | 2 | $34 |
| Johnson & Johnson | 2 | $29 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Tactile Systems Technology Inc | 1 | $24 |
| Merck | 1 | $24 |
| Qiagen, LLC | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,743 in reported general payments places this provider in the 85th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 153 | $175,471 |
| TrulicityDulaglutide | 102 | $121,333 |
| IngrezzaValbenazine Tosylate | 11 | $83,570 |
| JardianceEmpagliflozin | 58 | $73,902 |
| MyrbetriqMirabegron | 104 | $56,271 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 73 | $54,839 |
| JanuviaSitagliptin Phosphate | 42 | $51,567 |
| MounjaroTirzepatide | 40 | $42,192 |
| EliquisApixaban | 63 | $34,774 |
| XareltoRivaroxaban | 21 | $32,265 |
| TradjentaLinagliptin | 25 | $29,227 |
| CreonLipase/Protease/Amylase | 17 | $21,804 |
| FarxigaDapagliflozin Propanediol | 15 | $21,211 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $18,292 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 26 | $17,385 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $247 | $186,670165 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $746 | $163,525142 claims |
| Boehringer IngelheimJardiance, Tradjenta | $149 | $103,12883 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $532 | $67,184102 claims |
| Astellas Pharma US IncMyrbetriq | $84 | $56,271104 claims |
| AbbVieCreon, Vraylar, Linzess, Synthroid | $58 | $55,273129 claims |
| MerckJanuvia | $24 | $51,56742 claims |
| PfizerEliquis, Premarin | $262 | $43,02283 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $574 | $38,59641 claims |
| Johnson & JohnsonXarelto | $29 | $32,26521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Gulfport
- David PendleyGulfport$336K
- Mousa MaaloufGulfport$14K
- David LarosaGulfport$14K
- Phillip ComptonGulfport$10K
- Lynn LeatherwoodGulfport$10K
- Jay SegarraGulfport$9K
- Boyd BenefieldGulfport$7K
- James HallBrookhaven$4.8M
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.